A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma

被引：3
|
作者：
Wen, Patrick V.
Omuro, Antonio M.
Batchelor, Tracy T.
Lai, Albert
Mellinghoff, Ingo K.
Nghiemphu, Leia
Norden, Andrew
Gendreau, Steven B.
Laird, A. Douglas
Nguyen, Linh
Cloughesy, Timothy
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B265
引用
收藏
页数：3
相关论文
共 38 条
  • [21] A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    Dy, Grace K.
    Zhao, Yujie
    Ma, Wen Wee
    Opyrchal, Mateusz
    Bakhribah, Hatoon
    Jacob, Sandra M.
    O'Hara, Corrie
    Dozier, Askia
    Cmiljanovic, Natasa
    Todaro, Barbara
    Brady, William E.
    Schmitz, Debora
    Dimitrijevic, Sasa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 20, pg 233, 2014)
    Rodon, Jordi
    Shapiro, G., I
    Bedell, C.
    Kwak, E. L.
    Baselga, J.
    Brana, I
    CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2192 - 2192
  • [23] Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
    Coleman, Niamh
    Naing, Aung
    Zhang, Shizhen
    Piha-Paul, Sarina Anne Anne
    Tsimberidou, Apostolia Maria
    Janku, Filip
    Rodon, Jordi
    Pant, Shubham
    Dumbrava, Ecaterina Elena
    Fu, Siqing
    Hong, David S.
    Meric-Bernstam, Funda
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss
    Tawbi, Hussein Abdul-Hassan
    Peng, Weiyi
    Milton, Denai
    Amaria, Rodabe Navroze
    Glitza, Isabella Claudia
    Hwu, Wen-Jen
    Patel, Sapna Pradyuman
    Wong, Michael K. K.
    Woodman, Scott Eric
    Yee, Cassian
    McQuade, Jennifer Leigh
    Tetzlaff, Michael T.
    Lazar, Alexander J.
    Cain, Suzanne
    Burton, Elizabeth M.
    Beumer, Jan Hendrik
    Hwu, Patrick
    Davies, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy
    Choueiri, T. K.
    Porta, C.
    Rodriguez, C. Suarez
    Alter, R.
    Czaykowski, P.
    Duran, I.
    Gross-Goupil, M.
    Kalinka-Warzocha, E.
    Melichar, B.
    Patel, C.
    Neuwirth, R.
    Enke, A.
    Zohren, F.
    Powles, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
    Tawbi, Hussein Abdul-Hassan
    Peng, Weiyi
    Phillips, Suzanne
    Milton, Denai R.
    Amaria, Rodabe Navroze
    Diab, Adi
    Glitza, Isabella Claudia
    Patel, Sapna Pradyuman
    Wong, Michael K. K.
    Yee, Cassian
    McQuade, Jennifer Leigh
    Tetzlaff, Michael T.
    Lazar, Alexander J.
    Shephard, Michael
    Cain, Suzanne
    Burton, Elizabeth M.
    Hwu, Patrick
    Davies, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
    Colombo, I.
    Genta, S.
    Martorana, F.
    Guidi, M.
    Samartzis, E. S. P.
    Brandt, S.
    Gaggetta, S.
    Moser, L.
    Pascale, M. R.
    Terrot, T.
    Sessa, C.
    Stathis, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S487 - S487
  • [28] A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL)
    Forero-Torres, Andres
    Barr, Paul M.
    Diefenbach, Catherine S. Magid
    Sher, Taimur
    Schaub, Richard
    Zhou, Li
    Pulini, Jennifer
    Leopold, Lance
    Spear, Matthew A.
    Talpaz, Moshe
    Phillips, Tycel Jovelle
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] PIPA: A phase Ib study of selective β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers-Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
    Lopez, Juanita Suzanne
    SelviMiralles, Manuel
    Ameratunga, Malaka
    Minchom, Anna
    Pascual, Javier
    Banerji, Udai
    Bye, Hannah
    Raynaud, Florence I.
    Swales, Karen E.
    Malia, Jason
    Hubank, Michael
    Garcia-Murillas, Isaac
    Parmar, Mona
    Ward, Sarah Emily
    Finneran, Laura
    Hall, Emma
    Turner, Alison Joanne
    De Bono, Johann S.
    Yap, Timothy A.
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
    Phillips, Tycel Jovelle
    Forero-Torres, Andres
    Sher, Taimur
    Diefenbach, Catherine S. Magid
    Talpaz, Moshe
    Scherle, Peggy A.
    Schaub, Richard
    Zhou, Li
    Pulini, Jennifer
    Leopold, Lance
    Spear, Matthew A.
    Barr, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
1234